Stay updated on Risankizumab Maintenance in Psoriasis Clinical Trial
Sign up to get notified when there's something new on the Risankizumab Maintenance in Psoriasis Clinical Trial page.

Latest updates to the Risankizumab Maintenance in Psoriasis Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoChange Detected- Revision metadata updated: added v3.4.3 and removed v3.4.2.SummaryDifference0.0%

- Check17 days agoNo Change Detected
- Check31 days agoChange DetectedRevision updated from v3.4.1 to v3.4.2. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check38 days agoChange DetectedRevision label updated from v3.4.0 to v3.4.1. This appears to be a versioning update to the documentation with no changes to the study details.SummaryDifference0.0%

- Check52 days agoChange DetectedAdded: Show glossary; Last Update Submitted that Met QC Criteria; No FEAR Act Data; Revision: v3.4.0; Removed: Last Update Submitted that met QC Criteria; No FEAR Act data; Revision: v3.3.4. These changes affect only UI text and metadata and do not alter substantive study information, eligibility criteria, or results.SummaryDifference0.1%

- Check59 days agoChange DetectedRevision: v3.3.4 added. Revision: v3.3.3 removed.SummaryDifference0.0%

- Check88 days agoChange DetectedLocations section was reorganized into a single comprehensive list of participating sites across the US and various countries, consolidating numerous state and country entries. The previous per-location headings (e.g., Alabama Locations) were removed, and the HHS Vulnerability Disclosure link was deleted.SummaryDifference3%

Stay in the know with updates to Risankizumab Maintenance in Psoriasis Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Risankizumab Maintenance in Psoriasis Clinical Trial page.